COSMO Pharmaceuticals' Net Income page includes the metric definition, calculation formula, and current value. The calculation uses inputs from the most recent financial disclosure. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Net Income
=
(Rev + Gain)
-
(Exp + Loss)
=
-3.63 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales. COSMO Pharmaceuticals' Net Income reading is drawn from the most recently filed financial reports. All data reflects publicly available financial reports. The dataset reflects the latest available reporting timeframe. The information reflects the current reporting dataset.
Latest COSMO Pharmaceuticals' Net Loss Growth Pattern
Below is COSMO Pharmaceuticals' Net Loss history, covering 15 years of reported data. The shift from -3.6 M to -3.4 M represents the most recent annual movement. Gaps between consecutive data points reveal where COSMO Pharmaceuticals' Net Loss changed most rapidly.
Understanding the correlations between COSMO Pharmaceuticals' financial accounts, including Net Income, is fundamental to building accurate financial models for COSMO Pharmaceuticals. Because COSMO Pharmaceuticals' key financial indicators are all interdependent within its reporting framework, examining their correlations is more efficient than reviewing each statement independently.
Fiscal trend analysis indicates Accumulated Other Comprehensive Income is set to increase significantly relative to last year. COSMO Pharmaceuticals entered the current period with Accumulated Other Comprehensive Income of 9.78 Million on the books.
Based on the recorded statements, COSMO Pharmaceuticals SA reported net income of -3.63 Million. The Pharmaceuticals sector average is 101.06% above this level, and the Health Care industry average is 100.09% above. COSMO Pharmaceuticals is also 100.64% lower than the broader all Switzerland stocks average.
Fundamental Drivers Relationships
Peer multiple analysis evaluates COSMO Pharmaceuticals's pricing efficiency within its industry. Exploring the interplay between COSMO Pharmaceuticals' financial ratios and those of its competitors can uncover valuation signals that standalone analysis misses. More Info.
COSMO Pharmaceuticals SA is rated below average for net income across the peer group. It falls in the third position for return on asset across the peer group . Net Loss is developing negatively compared to historical levels. Year-ago financials show COSMO Pharmaceuticals with Net Loss of -3.63 Million. Comparative pricing ratios evaluate COSMO Pharmaceuticals against peer standards.
Net Income Peer Comparison
Stock peer comparison on Net Income is a widely used and accepted method for evaluating COSMO Pharmaceuticals relative to its direct and indirect competitors. Analyzing COSMO Pharmaceuticals' Net Income against that of similar stocks can help detect undervalued opportunities or identify better portfolio.
COSMO Pharmaceuticals is currently under evaluation for net income across the peer group.
Current Valuation Drivers
The valuation drivers for COSMO Pharmaceuticals are derived from an analysis of COSMO Pharmaceuticals' financial statements and used to calculate various performance and valuation scores. These indicators measure COSMO Pharmaceuticals' ability to generate profit relative to its revenue, operating costs, and shareholder equity.
COSMO Pharmaceuticals reports annual revenue of 104.85 M, a profit margin of 32.91%, ROE of 12.34%, debt-to-equity of 35.5. An assessment of COSMO Pharmaceuticals's core fundamentals focuses on profitability drivers and balance-sheet composition. Profitability regime consistency underpins valuation stability over time. Latest reported fundamentals for COSMO Pharmaceuticals include revenue of 104.85 M, positive EPS of 3.31, negative operating margin of 2.73%, current ratio of 24.38.
This section for COSMO Pharmaceuticals SA is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.